PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28485010-0	2017	The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma: A Nordic Lymphoma Group study.	Etoposide	16-25	ALK receptor tyrosine kinase	Homo sapiens	73-76	
28485010-8	2017	Our results suggest that the addition of etoposide to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) in the treatment for ALK+ ALCL seems reasonable in this age group.	Etoposide	41-50	ALK receptor tyrosine kinase	Homo sapiens	139-142	
29279550-7	2017	Patients with ALK-positive ALCL are usually treated with anthracycline-based regimens, such as combination cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) or CHOEP (CHOP plus etoposide), which provide a favorable prognosis, except in patients with multiple International Prognostic Index factors.	Etoposide	195-204	ALK receptor tyrosine kinase	Homo sapiens	14-17	
23568456-5	2013	Based on phase II evidence and subset analyses available, we believe that the addition of etoposide to standard regimens and consolidation of first remissions with autologous stem cell transplantation (autoSCT) provides the best outcome in patients with PTCL and currently use CHOEP followed by ASCT for eligible patients with the common PTCL subtype: PTCL-NOS, AITL, and ALK negative ALCL.	Etoposide	90-99	ALK receptor tyrosine kinase	Homo sapiens	372-375